These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31775034)

  • 1. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.
    Low MSY; Brodie EJ; Fedele PL; Liao Y; Grigoriadis G; Strasser A; Kallies A; Willis SN; Tellier J; Shi W; Gabriel S; O'Donnell K; Pitt C; Nutt SL; Tarlinton D
    Cell Rep; 2019 Nov; 29(9):2634-2645.e5. PubMed ID: 31775034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
    Agnarelli A; Chevassut T; Mancini EJ
    Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
    Bolomsky A; Ceribelli M; Scheich S; Rinaldi K; Huang DW; Chakraborty P; Pham L; Wright GW; Hsiao T; Morris V; Choi J; Phelan JD; Holewinski RJ; Andresson T; Wisniewski J; Riley D; Pittaluga S; Hill E; Thomas CJ; Muppidi J; Young RM
    Cancer Cell; 2024 Jul; 42(7):1185-1201.e14. PubMed ID: 38906156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
    Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
    Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IRF4 addiction in multiple myeloma.
    Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
    Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
    Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
    Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
    Ikeda S; Tagawa H
    Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.
    Zhang S; Xu J; Wu S; Wang R; Qu X; Yu W; Li J; Chen L
    Med Oncol; 2013; 30(2):594. PubMed ID: 23666852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
    Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
    Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism.
    Willis SN; Good-Jacobson KL; Curtis J; Light A; Tellier J; Shi W; Smyth GK; Tarlinton DM; Belz GT; Corcoran LM; Kallies A; Nutt SL
    J Immunol; 2014 Apr; 192(7):3200-6. PubMed ID: 24591370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
    Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
    Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
    Ohguchi H; Hideshima T; Bhasin MK; Gorgun GT; Santo L; Cea M; Samur MK; Mimura N; Suzuki R; Tai YT; Carrasco RD; Raje N; Richardson PG; Munshi NC; Harigae H; Sanda T; Sakai J; Anderson KC
    Nat Commun; 2016 Jan; 7():10258. PubMed ID: 26728187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
    Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
    Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.
    Ramos-Vara JA; Miller MA; Valli VE
    Vet Pathol; 2007 Nov; 44(6):875-84. PubMed ID: 18039900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.
    Kassambara A; Jourdan M; Bruyer A; Robert N; Pantesco V; Elemento O; Klein B; Moreaux J
    Nucleic Acids Res; 2017 Jun; 45(10):5639-5652. PubMed ID: 28459970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRF4: Immunity. Malignancy! Therapy?
    Shaffer AL; Emre NC; Romesser PB; Staudt LM
    Clin Cancer Res; 2009 May; 15(9):2954-61. PubMed ID: 19383829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
    Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
    Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
    Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
    Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc finger-IRF composite elements bound by Ikaros/IRF4 complexes function as gene repression in plasma cell.
    Ochiai K; Kondo H; Okamura Y; Shima H; Kurokochi Y; Kimura K; Funayama R; Nagashima T; Nakayama K; Yui K; Kinoshita K; Igarashi K
    Blood Adv; 2018 Apr; 2(8):883-894. PubMed ID: 29669755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
    Perini T; Materozzi M; Milan E
    FEBS J; 2022 Aug; 289(15):4383-4397. PubMed ID: 34117720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.